An Exploration on Trematodes and cestodes in humans
Md.Shahbaz Alam
Zoology
September 2021
Praziquantel usage for treating human trematode and cestode infections is briefly reviewed, along with status and new concerns. Numerous studies have shown the effective use of praziquantel in the management of the majority of human-infecting trematodes and cestodes since it was originally marketed as a broadspectrum anthelmintic in 1975. The following trematode and cestode disorders are among those that are targeted for treatment: schistosomiasis, clonorchiasis, opisthorchiasis, paragonimiasis, heterophyidiasis, echinostomiasis, fasciolopsiasis, neodiplostomiasis, gymnophalloidiasis, taeniases, diphyllobothria Praziquantel, however, is ineffective against Fasciola hepatica and Fasciola gigantica infections; thus, triclabendazole, a different medication, is required. Praziquantel also fails to effectively treat larval cestode infections, including hydatid disease and sparganosis. Praziquantel's exact mode of action is still not fully known. Along with allergic or hypersensitive responses to praziquantel treatment, there are also new issues with praziquantel therapy, such as the development of drug resistance in the treatment of Schistosoma mansoni and probably Schistosoma japonicum. Combining the usage of medications, such as praziquantel and other recently released substances like triclabendazole, artemisinins, and tribendimidine, is being tested as a means of coping with and resolving these issues.
© Airo Journals 2021
